Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Hepatitis B Virus Therapy
Study data from Oxford University, Nuffield Department of Clinical Medicine provide new insights into hepatitis B virus therapy
October 1st, 2008
Scientists discuss in 'Direct ex vivo evaluation of long-lived protective antiviral memory B cell responses against hepatitis B virus' new findings in hepatitis B virus. According to recent research from Oxford, the United Kingdom, "The frequency of protective antiviral memory B cells after hepatitis B virus (HBV) vaccination is unknown. A novel 2-step immunomagnetic protocol to assess the ex vivo frequency of protective HBV surface antigen (HBsAg)-specific memory B cells was used." "HBsAg-specific memory B cells were detected in vaccinated individuals, although at very low frequency (median, 0.2% of CD19(+) cells [range, 0%-4% of CD19(+) cells]). No correlation existed...
Source: Vaccine Weekly (2008-10-01)
|
